Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
All content for Fenben® Voices is the property of Fenbendazole Help and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
S2EP3 How Fenbendazole And Ivermectin Could Reshape Cancer Care
Fenben® Voices
16 minutes
2 weeks ago
S2EP3 How Fenbendazole And Ivermectin Could Reshape Cancer Care
Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
Fenben® Voices
Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
